IRIS
GOZZO, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.022
AS - Asia 1.707
EU - Europa 1.257
AF - Africa 206
SA - Sud America 190
OC - Oceania 6
Totale 5.388
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.972
SG - Singapore 744
CN - Cina 583
RU - Federazione Russa 531
IT - Italia 295
BR - Brasile 168
KR - Corea 166
IE - Irlanda 165
VN - Vietnam 99
CI - Costa d'Avorio 79
FR - Francia 57
SN - Senegal 39
NG - Nigeria 37
IN - India 35
NL - Olanda 33
FI - Finlandia 30
GB - Regno Unito 29
CA - Canada 28
BJ - Benin 19
SE - Svezia 19
DE - Germania 18
PL - Polonia 18
ZA - Sudafrica 17
BD - Bangladesh 15
JP - Giappone 15
ES - Italia 14
MX - Messico 12
UA - Ucraina 12
BE - Belgio 11
AR - Argentina 8
AU - Australia 6
TR - Turchia 6
IQ - Iraq 5
KE - Kenya 5
AL - Albania 4
AT - Austria 4
HK - Hong Kong 4
PK - Pakistan 4
VE - Venezuela 4
CR - Costa Rica 3
CY - Cipro 3
DZ - Algeria 3
GR - Grecia 3
IL - Israele 3
JM - Giamaica 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BS - Bahamas 2
CL - Cile 2
CO - Colombia 2
CZ - Repubblica Ceca 2
EG - Egitto 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
NO - Norvegia 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
RO - Romania 2
SA - Arabia Saudita 2
UY - Uruguay 2
UZ - Uzbekistan 2
AO - Angola 1
BB - Barbados 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CH - Svizzera 1
DK - Danimarca 1
EC - Ecuador 1
GM - Gambi 1
HN - Honduras 1
ID - Indonesia 1
IR - Iran 1
IS - Islanda 1
LB - Libano 1
LT - Lituania 1
MN - Mongolia 1
MW - Malawi 1
NP - Nepal 1
PE - Perù 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TJ - Tagikistan 1
Totale 5.388
Salva come PNG Salva come JPEG
Città #
Singapore 445
Santa Clara 390
Dallas 347
Hefei 311
Moscow 230
Ashburn 183
San Jose 179
Seoul 166
Dublin 164
Chicago 86
Boardman 80
Abidjan 79
Chandler 64
Beijing 55
Los Angeles 54
Lauterbourg 53
Council Bluffs 44
Ho Chi Minh City 41
Civitanova Marche 39
Dakar 39
Catania 34
New York 34
Rome 30
Amsterdam 27
Hanoi 21
Cotonou 19
Stockholm 19
Washington 19
Lagos 18
Warsaw 18
Abuja 17
São Paulo 17
Lappeenranta 15
Orem 14
Palermo 14
Milan 13
Tokyo 13
Buffalo 12
Brussels 11
Johannesburg 11
Montreal 11
Pune 11
Boston 10
Chennai 10
Brooklyn 9
Campobasso 9
Phoenix 9
Helsinki 8
Manchester 8
Seattle 8
Atlanta 7
Cambridge 7
Lawrence 7
Rio de Janeiro 7
Andover 6
Denver 6
London 6
Munich 6
Poplar 6
Des Moines 5
Jacksonville 5
Assago 4
Assoro 4
Augusta 4
Belo Horizonte 4
Bologna 4
Charlotte 4
City of London 4
Da Nang 4
Dong Ket 4
Florence 4
Gela 4
Hong Kong 4
Melbourne 4
Milwaukee 4
Reggio Calabria 4
Secaucus 4
Trento 4
Turku 4
Acalanes Ridge 3
Anápolis 3
Castelraimondo 3
Columbus 3
Espoo 3
Frankfurt am Main 3
Guarulhos 3
Houston 3
Kingston 3
Kirkuk 3
Lamezia Terme 3
Messina 3
Mexico City 3
Miami 3
Montesilvano 3
Mumbai 3
Nairobi 3
Nicosia 3
Piazzola Sul Brenta 3
Querétaro 3
Redondo Beach 3
Totale 3.721
Salva come PNG Salva come JPEG
Nome #
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 161
The antineoplastic drug flavopiridol reverses memory impairment induced by Amyloid-ß1-42 oligomers in mice 160
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 147
Efficacy and Safety of Subthreshold Micropulse Yellow Laser for Persistent Diabetic Macular Edema After Vitrectomy: A Pilot Study 145
Do the current performance-based schemes in Italy really work? "Success fee": a novel measure for cost-containment of drug expenditure 143
Accesso ai medicinali innovativi per indicazioni neurologiche in Europa: allineamento delle valutazioni di Health Technology Assessment tra i Paesi Europei 141
Fluoxetine Protects Retinal Ischemic Damage in Mice 137
Off-label use of drugs and adverse drug reactions in pediatric units: A prospective, multicenter study 135
Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries 135
4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation 121
Editorial: Innovation in ocular pharmacology 120
Linking the Price of Cancer Drug Treatments to Their Clinical Value 116
EMA: l’ente che vigila sui medicinali che circolano nella Comunità Europea 114
Flavan-3-ols and Vascular Health: Clinical Evidence and Mechanisms of Action 111
Severe Gastrointestinal Toxicity Following the Use of Gilteritinib: A Case Series and Analysis of Postmarketing Surveillance Data 111
Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough? 109
The dual blocker of FAAH/TRPV1 N-arachidonoylserotonin reverses the behavioral despair induced by stress in rats and modulates the HPA-axis 107
Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network 106
Long-term efficacy and safety profile of multiple injections of intravitreal dexamethasone implant to manage diabetic macular edema: A systematic review of real-world studies 106
Health Technology Assessment of Advanced Therapy Medicinal Products: Comparison Among 3 European Countries 105
Early Access for Medicines in ITALY: The Case of Ruxolitinib for Patients with Graft-Versus-Host Disease 103
Fertility Preservation in Female Pediatric Patients With Cancer: A Clinical and Regulatory Issue 103
Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution 101
Response to Letter to the Editor by Dr. Garattini 99
Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval? 98
AIFA: l’ente che autorizza un nuovo farmaco, una nuova formulazione o una nuova indicazione in Italia 95
New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review 95
Sviluppo ed uso dei farmaci: dal laboratorio alla clinica. 94
Dexamethasone Treatment for Covid-19, a Curious Precedent Highlighting a Regulatory Gap 91
COVID-19 Disease and Vitamin D: A Mini-Review 91
Beyond the budget silo approach: estimating health system sustainability for future dementia drugs 90
How many chronic myeloid leukemia patients who started a frontline second-generation tyrosine kinase inhibitor have to switch to a second-line treatment? A retrospective analysis from the monitoring registries of the italian medicines agency (AIFA) 88
Non-vitamin K antagonist oral anticoagulation agents in patients with atrial fibrillation: Insights from Italian monitoring registries 85
Attitude survey of spontaneous adverse drug-reaction reporting by general practitioners in Sicily 83
Editorial: Innovative treatments for neuro-psychiatric diseases 82
Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiota 81
OFF-LABEL USE OF MEDICINES: A CLINICAL AND REGULATORY OPPORTUNITYTHE. 40TH CONGRESS OF THE ITALIAN PHARMACOLOGICAL SOCIETY (SIF) 81
Anemia Mediterranea o talassemia: c’è qualcosa per evitare le trasfusioni? 77
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA) 76
Isoflavones Effects on Vascular and Endothelial Outcomes: How Is the Gut Microbiota Involved? 74
Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence 72
Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2019. Roma: Agenzia Italiana del Farmaco, 2020. 69
Starting dose and dose adjustment of non-vitamin K antagonist oral anticoagulation agents in a nationwide cohort of patients with atrial fibrillation 69
Scheda informativa Tocilizumab per uso endovenoso nel trattamento di pazienti gravi con COVID-19 68
La sclerosi multipla: una malattia invalidante con nuove possibilità di cura 67
Obesità e farmaci: quando servono e quali usare 66
Periodontal Disease and Pregnancy: Correlation with Underweight Birth 66
The Regulatory Challenges for Drug Repurposing During the Covid-19 Pandemic: The Italian Experience 63
Starting Dose Of Non-Vitamin K Antagonist Oral Anticoagulation Agents In Patients With Atrial Fibrillation: Data From Italian Monitoring Registries 63
The therapeutic value of treatment for multiple sclerosis: analysis of health technology assessments of three European countries 61
Towards a European harmonization of health technology assessment recommendations executive paper of European regulatory conference focused on the EU commission proposal to harmonize HTA 60
Più che una speranza, oggi è una certezza la possibilità di ridurre la gravità dell’atrofia muscolare spinale 60
The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review 59
Prevenzione e terapia dell’osteoporosi: quali farmaci sono utili e cosa c’è di nuovo 58
SARS-Cov-2 Damage on the Nervous System and Mental Health 56
Quali farmaci usare per l’età pediatrica? 55
Osservatorio Nazionale sull’impiego dei Medicinali. L’uso dei farmaci in Italia. Rapporto Nazionale Anno 2018. Roma: Agenzia Italiana del Farmaco, 2019 55
Phase II, noncomparative, open label, multicenter, study of osimertinib, in patients with locally advanced or metastatic EGFR mutated, T790M undetectable or unknown non-small cell lung cancer (Stage IIIB-IV) after no immediate prior EGFR TKI (OSIRIS study) 52
Asma: vecchi e nuovi farmaci e attenzione al CoViD-19 50
Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database 23
Totale 5.509
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.272
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.272
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202111 0 0 0 0 0 0 0 0 0 3 3 5
2021/202275 1 6 3 1 8 5 6 1 10 10 5 19
2022/2023500 8 11 4 10 80 99 31 102 118 1 24 12
2023/2024448 18 58 35 42 26 97 21 39 3 13 62 34
2024/20251.404 19 161 62 64 312 162 71 40 91 110 135 177
2025/20263.047 256 396 409 212 461 647 315 48 153 150 0 0
Totale 5.509